Obagi’s ELASTIderm™ increases skin elasticity in 6 weeks
Obagi Medical Products, Inc has announced the publication of a study of its copper-zinc malonate eye treatment ELASTIderm™ in the September 2008 issue of the dermatology journal, Experimental Dermatology. Findings of the study conducted at Jefferson Medical College suggest that six weeks of ELASTIderm treatment can boost the biosynthesis of elastin in skin helping to repair and regenerate the elastic fiber network. It reduces the number of visible wrinkles by restoring the skin’s elasticity. The product uses a bi-mineral complex technology.

The U.S. Food and Drug Administration has approved safety labeling revisions for
Results of a prospective multi-center clinical trial show that a long-term, low-dose schedule of ethinyl estradiol and norethindrone acetate does not prevent age-related changes in skin surface. Researchers from Boston University revealed that there was no significant improvement in the skin structure after the end of a year long low-dose hormone therapy. The mean age of the 485 women enrolled in the trial was 53.6 years. Instead they recommended regular basic care through products like Renova that can save the skin from photo-damage.
Elemé™ Medical Inc. has received CE Mark approval for its
Drug maker Dr Reddy’s Laboratories has entered into a licensing and distribution agreement with a American dermatology and aesthetic medicine company Cosmederm Technologies for distribution of proprietary skin care products in India. The agreement, as of now, covers only two products, Refinity and Cosmederm peel kits that contain Glycolic acid, which improve the color, glow and tone of the skin, in significant quantities.